Company registration number 05826113 (England and Wales)
Clinova Limited
Unaudited Financial Statements
For The Year Ended 31 October 2024
Pages For Filing With Registrar
CLINOVA LIMITED
Clinova Limited
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 14
CLINOVA LIMITED
Clinova Limited
BALANCE SHEET
AS AT 31 OCTOBER 2024
31 October 2024
- 1 -
2024
2023
as restated
Notes
£
£
£
£
Fixed assets
Intangible assets
3
5,579
7,438
Tangible assets
4
19,131
25,570
Investments
5
4,002
2
28,712
33,010
Current assets
Stocks
326,457
545,008
Debtors
7
2,486,298
1,606,526
Cash at bank and in hand
31,022
5,842
2,843,777
2,157,376
Creditors: amounts falling due within one year
8
(3,946,605)
(2,097,582)
Net current (liabilities)/assets
(1,102,828)
59,794
Total assets less current liabilities
(1,074,116)
92,804
Creditors: amounts falling due after more than one year
9
-
0
(83,168)
Provisions for liabilities
(4,858)
(4,858)
Net (liabilities)/assets
(1,078,974)
4,778
Capital and reserves
Called up share capital
1,477
1,466
Share premium account
16,425,935
15,246,945
Equity reserve
3,036,640
2,598,253
Capital redemption reserve
11
11
Other reserves
45,118
-
0
Profit and loss reserves
(20,588,155)
(17,841,897)
Total equity
(1,078,974)
4,778
CLINOVA LIMITED
Clinova Limited
BALANCE SHEET (CONTINUED)
AS AT 31 OCTOBER 2024
31 October 2024
- 2 -

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 October 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 31 October 2025 and are signed on its behalf by:
Mr C Ebubedike
Director
Company Registration No. 05826113
CLINOVA LIMITED
Clinova Limited
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
- 3 -
1
Accounting policies
Company information

Clinova Limited (the 'Company') is a private company limited by shares incorporated in England and Wales. The registered office is International House, Southampton International Business Park, George Curl Way, Southampton, Hampshire, SO18 2RZ. The Company's principal activities and nature of its operations are disclosed in the directors' report.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are for Clinova Limited as an individual entity and are prepared in sterling, which is the functional currency of the Company. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

These financial statements for the year ended 31 October 2024 are the first financial statements of Clinova Limited prepared in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland. The date of transition to FRS 102 was 1 November 2022. An explanation of how transition to FRS 102 has affected the reported financial position and financial performance is given in note 13.

The company has taken advantage of the exemption under section 399 of the Companies Act 2006 not to prepare consolidated accounts, on the basis that the group of which this is the parent qualifies as a small group. The financial statements present information about the company as an individual entity and not about its group.

1.2
Going concern

The directors have at the time of approving the financial statements, a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. There is further and continued support from the directors and shareholders regards to ongoing financing of the business. Therefore, the going concern basis of accounts continues to be appropriate.true

 

The company continues to be in a growth phase, concentrating on expanding its customer base. These activities have been supported through a combination of the company’s existing facilities and the issuance of shares to raise further capital. After the year end the company has raised further equity funding to support on-going operations and growth.

1.3
Turnover

Turnover is measured based on the consideration specified in a contract with a customer and excludes amounts collected on behalf of third parties. The Company recognises revenue when it transfers control of a product to a customer.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

CLINOVA LIMITED
Clinova Limited
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
1
Accounting policies
(Continued)
- 4 -
1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets comprise primarily website development costs and intellectual property. Such assets are defined as having finite useful lives and the costs are amortised over their estimated useful lives as listed below.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Intellectual property
20% on a straight line basis
Website
25% reducing balance

Intangible assets are reviewed for impairment whenever there is an indication that the carrying value may be impaired.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures & fittings
25% reducing balance
Computer equipment
25% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Fixed asset investments

Interests in subsidiaries are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.7
Impairment of fixed assets

At each reporting end date, the Company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

CLINOVA LIMITED
Clinova Limited
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
1
Accounting policies
(Continued)
- 5 -

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.8
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.9
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.10
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

CLINOVA LIMITED
Clinova Limited
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
1
Accounting policies
(Continued)
- 6 -
Other financial assets

Financial instruments are classified as financial assets measured at amortised cost where the objective is to hold these assets in order to collect contractual cash flows, and the contractual cash flows are solely payments of principal and interest. They arise principally from the provision of goods and services to customers (e.g. trade receivables). They are initially recognised at fair value plus transaction costs directly attributable to their acquisition or issue, and are subsequently carried at amortised cost using the effective interest rate method, less provision for impairment where necessary.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

CLINOVA LIMITED
Clinova Limited
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
1
Accounting policies
(Continued)
- 7 -
1.11
Compound instruments

The component parts of compound instruments issued by the company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangement. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a similar non-convertible instrument. This amount is recorded as a liability on an amortised cost basis using the effective interest method until extinguished upon conversion or at the instrument's maturity date. The equity component is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognised and included in equity net of income tax effects and is not subsequently remeasured.

1.12
Equity instruments

Equity instruments issued by the Company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the Company.

1.13
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The Company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax is the tax expected to be payable or recoverable on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit, and is accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised. Such assets and liabilities are not recognised if the temporary difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the Company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.14
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of inventories or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the Company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

CLINOVA LIMITED
Clinova Limited
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
1
Accounting policies
(Continued)
- 8 -
1.15
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.16
Share-based payments

Equity-settled share-based payments are measured at fair value at the date of grant by reference to the fair value of the equity instruments granted using an asset-based valuation methodology. The fair value determined at the grant date is expensed on a straight-line basis over the vesting period, based on the estimate of shares that will eventually vest. A corresponding adjustment is made to equity.

When the terms and conditions of equity-settled share-based payments at the time they were granted are subsequently modified, the fair value of the share-based payment under the original terms and conditions and under the modified terms and conditions are both determined at the date of the modification. Any excess of the modified fair value over the original fair value is recognised over the remaining vesting period in addition to the grant date fair value of the original share-based payment. The share-based payment expense is not adjusted if the modified fair value is less than the original fair value.

 

Cancellations or settlements (including those resulting from employee redundancies) are treated as an acceleration of vesting and the amount that would have been recognised over the remaining vesting period is recognised immediately.

1.17
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.18
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the Company during the year was:

2024
2023
Number
Number
Total
10
12
CLINOVA LIMITED
Clinova Limited
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 9 -
3
Intangible fixed assets
Intellectual property
Website
Total
£
£
£
Cost
At 1 November 2023 and 31 October 2024
57,445
19,228
76,673
Amortisation and impairment
At 1 November 2023
57,445
11,790
69,235
Amortisation charged for the year
-
0
1,859
1,859
At 31 October 2024
57,445
13,649
71,094
Carrying amount
At 31 October 2024
-
0
5,579
5,579
At 31 October 2023
-
0
7,438
7,438
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 November 2023 and 31 October 2024
63,111
Depreciation and impairment
At 1 November 2023
37,541
Depreciation charged in the year
6,439
At 31 October 2024
43,980
Carrying amount
At 31 October 2024
19,131
At 31 October 2023
25,570
5
Fixed asset investments
2024
2023
£
£
Shares in group undertakings and participating interests
4,002
2
CLINOVA LIMITED
Clinova Limited
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
5
Fixed asset investments
(Continued)
- 10 -
Movements in fixed asset investments
Shares in subsidiaries
£
Cost or valuation
At 1 November 2023
2
Additions
4,000
At 31 October 2024
4,002
Carrying amount
At 31 October 2024
4,002
At 31 October 2023
2
6
Subsidiaries

Details of the Company's subsidiaries at 31 October 2024 are as follows:

Name of undertaking
Registered office
Class of
% Held
shares held
Direct
Indirect
CAIDR Limited
International House, George Curl Way, Southampton, Hampshire, England, SO18 2RZ
Ordinary
100.00
-
Healthwords Limited
2 Sycamore Street, London, England, EC1Y 0SF
Ordinary
100.00
-
O.R.S. Hydration Limited
2 Sycamore Street, London, England, EC1Y 0SF
Ordinary
100.00
-
Healthwords.ai Limited
2 Sycamore Street, London, United Kingdom, EC1Y 0SF
Ordinary
0
100.00
7
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
1,650,765
1,310,728
Corporation tax recoverable
129,606
109,987
Amounts owed by group undertakings
460,576
-
0
Other debtors
245,351
185,811
2,486,298
1,606,526

Amounts owed by group undertakings are interest free, unsecured and have no fixed day of repayment.

CLINOVA LIMITED
Clinova Limited
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 11 -
8
Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans and overdrafts
22,437
14,461
Convertible loans
1,426,799
387,903
Trade creditors
1,414,214
1,314,508
Amounts owed to group undertakings
1
1
Taxation and social security
114,536
24,030
Other creditors
968,618
356,679
3,946,605
2,097,582

Convertible loan notes

 

During the year, additional convertible loan notes were issued with proceeds totalling £938,605. The agreements incorporate a option to convert into shares. The loan notes are not secured.

 

The convertible loan notes are a compound instrument per section 22 due to resulting in a fixed number of ordinary shares upon conversion. The net proceeds received from the issue have therefore been split between the financial liability element and an equity component, representing the fair value of the option to convert the financial liability into equity. As a result, £45,118 was classified as equity and the remaining £893,487 as a liability.

 

Interest and discount unwinding of £103,071 and £3,330 foreign exchange gains have been recognised in relation to convertible loan notes in the year.

 

During the year, repayments of £37,500 were made.

 

The convertible loan notes have varying maturity dates all within one year.

 

The accounting treatment of the loans is similar to the valuing of equivalent non-convertible loans.

9
Creditors: amounts falling due after more than one year
2024
2023
£
£
Convertible loans
-
0
83,168
10
Share-based payment transactions

The Company has a share option scheme for certain employees. Options are exercisable at values between £0.01 and £1. The vesting period is 4 years. If the options remain unexercised after a period of ten years from the date of grant, the options expire. Options are forfeited if the employee leaves the Company before the options vest.

 

The Company has a share option scheme for certain individuals other than employees. Options are exercisable at a price pre-agreed on the date of grant but may only be exercised upon certain qualifying criteria being met. The options are immediately vested upon issue or within 3 years of issue. Options remain unexercised until the qualifying event. There is no means of forfeit attached to the option.

CLINOVA LIMITED
Clinova Limited
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
10
Share-based payment transactions
(Continued)
- 12 -
Number of share options
Weighted average exercise price
2024
2023
2024
2023
Number
Number
£
£
Outstanding at 1 November 2023
7,894
7,593
5.78
6.13
Granted
585
617
1.00
1.00
Forfeited
-
0
(316)
0
-
0
1.00
Outstanding at 31 October 2024
8,479
7,894
5.49
5.78
Exercisable at 31 October 2024
8,379
7,857
5.51
5.83

The options outstanding at 31 October 2024 had an exercise price ranging from £0.01 to £50.00, and a remaining contractual life of 4.8 years (2023: 4.5 years).

During the current and prior years, the company entered into share-based payment transactions with individuals other than employees in exchange for the provision of goods and services measured at the market price of the goods and services received. The exercise date is contingent upon certain qualifying criteria being met. An expense of £470,335 (2023: £671,999) was recognised in the statement of comprehensive income relating to this scheme.

Direct Measurement

The Company has measured the fair value of assets acquired during the current period using comparable transactions at market price upon which the options were granted.

11
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2024
2023
£
£
88,226
135,425
12
Related party transactions

The Company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

 

At the year end, amounts totalling £336,082 were due to the directors. This balance is interest free, unsecured and repayable on demand.

CLINOVA LIMITED
Clinova Limited
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 13 -
13
Reconciliations on adoption of FRS 102
Reconciliation of equity
At 1 November 2022
At 31 October 2023
IFRS
Effect of
transition
FRS 102
IFRS
Effect of
transition
FRS 102
Notes
£
£
£
£
£
£
Fixed assets
Other intangibles
21,406
-
21,406
7,438
-
7,438
Tangible assets
1
199,292
(174,424)
24,868
154,948
(129,378)
25,570
Investments
1
-
1
2
-
2
220,699
(174,424)
46,275
162,388
(129,378)
33,010
Current assets
Stocks
809,769
-
809,769
545,008
-
545,008
Debtors
2,043,232
-
2,043,232
1,606,526
-
1,606,526
Bank and cash
165,092
-
165,092
5,842
-
5,842
3,018,093
-
3,018,093
2,157,376
-
2,157,376
Creditors due within one year
Loans and overdrafts
(1,068)
-
(1,068)
(261,543)
-
(261,543)
Finance leases
1
(42,149)
42,149
-
(44,193)
44,193
-
0
Convertible loans
-
-
-
(387,903)
-
(387,903)
Taxation
(34,214)
-
(34,214)
(24,030)
-
(24,030)
Other creditors
(970,450)
-
(970,450)
(1,359,159)
-
(1,359,159)
Deferred income
-
-
-
(64,947)
-
(64,947)
(1,047,881)
42,149
(1,005,732)
(2,141,775)
44,193
(2,097,582)
Net current assets
1,970,212
42,149
2,012,361
15,601
44,193
59,794
Total assets less current liabilities
2,190,911
(132,275)
2,058,636
177,989
(85,185)
92,804
Creditors due after one year
Finance leases
1
(123,903)
123,903
-
(80,047)
80,047
-
0
Convertible loans
-
-
-
(83,168)
-
(83,168)
(123,903)
123,903
-
(163,215)
80,047
(83,168)
Provisions for liabilities
Deferred tax
(4,723)
-
(4,723)
(4,858)
-
(4,858)
Net assets
2,062,285
(8,372)
2,053,913
9,916
(5,138)
4,778
CLINOVA LIMITED
Clinova Limited
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
13
Reconciliations on adoption of FRS 102
At 1 November 2022
At 31 October 2023
IFRS
Effect of
transition
FRS 102
IFRS
Effect of
transition
FRS 102
Notes
£
£
£
£
£
£
(Continued)
- 14 -
Capital and reserves
Share capital
1,458
-
0
1,458
1,466
-
1,466
Share premium
14,242,329
-
0
14,242,329
15,246,945
-
15,246,945
Equity reserve
1,938,113
-
0
1,938,113
2,598,253
-
2,598,253
Capital redemption
11
-
0
11
11
-
11
Profit and loss
1
(14,119,626)
(8,372)
(14,127,998)
(17,836,759)
(5,138)
(17,841,897)
Total equity
2,062,285
(8,372)
2,053,913
9,916
(5,138)
4,778
Notes to reconciliations on adoption of FRS 102
Operating leases

Right of use assets and the associated lease liabilities have been derecognised and operating leases are now recognised straight line.

2024-10-312023-11-01falsefalsefalseCCH SoftwareCCH Accounts Production 2025.300No description of principal activityMr C EbubedikeMr A KarimMr C Ebubedike058261132023-11-012024-10-31058261132024-10-31058261132023-10-3105826113core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2024-10-3105826113core:Non-standardIntangibleAssetClass2ComponentIntangibleAssetsOtherThanGoodwill2024-10-3105826113core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2023-10-3105826113core:Non-standardIntangibleAssetClass2ComponentIntangibleAssetsOtherThanGoodwill2023-10-3105826113core:OtherResidualIntangibleAssets2023-10-3105826113core:IntangibleAssetsOtherThanGoodwill2023-10-3105826113core:OtherPropertyPlantEquipment2024-10-3105826113core:OtherPropertyPlantEquipment2023-10-3105826113core:CurrentFinancialInstrumentscore:WithinOneYear2024-10-3105826113core:CurrentFinancialInstrumentscore:WithinOneYear2023-10-3105826113core:Non-currentFinancialInstrumentscore:AfterOneYear2024-10-3105826113core:Non-currentFinancialInstrumentscore:AfterOneYear2023-10-3105826113core:CurrentFinancialInstruments2024-10-3105826113core:CurrentFinancialInstruments2023-10-3105826113core:ShareCapital2024-10-3105826113core:ShareCapital2023-10-3105826113core:SharePremium2024-10-3105826113core:SharePremium2023-10-3105826113core:OtherReservesSubtotal2024-10-3105826113core:OtherReservesSubtotal2023-10-3105826113core:CapitalRedemptionReserve2024-10-3105826113core:CapitalRedemptionReserve2023-10-3105826113core:OtherMiscellaneousReserve2024-10-3105826113core:OtherMiscellaneousReserve2023-10-3105826113core:RetainedEarningsAccumulatedLosses2024-10-3105826113core:RetainedEarningsAccumulatedLosses2023-10-3105826113core:ShareCapitalcore:IncreaseDecreaseDueToTransitionFromPreviousStandard2022-10-3105826113core:SharePremiumcore:IncreaseDecreaseDueToTransitionFromPreviousStandard2022-10-3105826113core:OtherReservesSubtotalcore:IncreaseDecreaseDueToTransitionFromPreviousStandard2022-10-3105826113core:CapitalRedemptionReservecore:IncreaseDecreaseDueToTransitionFromPreviousStandard2022-10-3105826113core:RetainedEarningsAccumulatedLossescore:IncreaseDecreaseDueToTransitionFromPreviousStandard2022-10-3105826113bus:CompanySecretaryDirector12023-11-012024-10-3105826113core:IntangibleAssetsOtherThanGoodwill2023-11-012024-10-3105826113core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2023-11-012024-10-3105826113core:Non-standardIntangibleAssetClass2ComponentIntangibleAssetsOtherThanGoodwill2023-11-012024-10-3105826113core:FurnitureFittings2023-11-012024-10-3105826113core:ComputerEquipment2023-11-012024-10-31058261132022-11-012023-10-3105826113core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2023-10-3105826113core:Non-standardIntangibleAssetClass2ComponentIntangibleAssetsOtherThanGoodwill2023-10-31058261132023-10-3105826113core:OtherPropertyPlantEquipment2023-10-3105826113core:OtherPropertyPlantEquipment2023-11-012024-10-3105826113core:Subsidiary12023-11-012024-10-3105826113core:Subsidiary22023-11-012024-10-3105826113core:Subsidiary32023-11-012024-10-3105826113core:Subsidiary42023-11-012024-10-3105826113core:Subsidiary112023-11-012024-10-3105826113core:Subsidiary222023-11-012024-10-3105826113core:Subsidiary332023-11-012024-10-3105826113core:Subsidiary442023-11-012024-10-3105826113core:Non-currentFinancialInstruments2024-10-3105826113core:Non-currentFinancialInstruments2023-10-31058261132022-10-3105826113core:IncreaseDecreaseDueToTransitionFromPreviousStandard2023-10-3105826113bus:PrivateLimitedCompanyLtd2023-11-012024-10-3105826113bus:SmallCompaniesRegimeForAccounts2023-11-012024-10-3105826113bus:FRS1022023-11-012024-10-3105826113bus:AuditExempt-NoAccountantsReport2023-11-012024-10-3105826113bus:Director12023-11-012024-10-3105826113bus:Director22023-11-012024-10-3105826113bus:CompanySecretary12023-11-012024-10-3105826113bus:FullAccounts2023-11-012024-10-31xbrli:purexbrli:sharesiso4217:GBP